Gsk's rsv vaccine candidate for older adults, containing agenus' qs-21 stimulon™ as part of gsk's as01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions

Lexington, mass., june 10, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to cancer and infections, today shared that partner gsk announced positive headline results from a pre-specified efficacy interim analysis of the aresvi 006 phase iii trial evaluating their investigational rsv vaccine in adults aged 60 years and above. the primary endpoint was exceeded with no unexpected safety concerns observed. engagement with regulators is planned to start immediately with anticipated regulatory submissions in h2 2022.
AGEN Ratings Summary
AGEN Quant Ranking